2024年10月4日,Nature在其官网头条位置,报道了一项由中国科学家团队在Cell杂志上发表的研究成果-World-first therapy using donor cells sends autoimmune diseases into remission(世界上第一个使用供体细胞的疗法可以缓解自身免疫性疾病)。 文献解读 文章:Allogeneic CD19-targeted CAR-T therapy in patients with seve...
近期,Nature期刊上发表了题为“Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL”的研究论文,旨在探究基于CRISPR–Cas9技术的非病毒、基因特异性靶向CAR-T细胞的安全性和有效性。 图源| nature....
3. Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.Sci. Transl. Med.11, eaav1648 (2019). 4. Jin, X. et al. Therapeutic efficacy ...
3.Baker DJ, June CH. CAR T therapy extends its reach to autoimmune diseases. Cell. 2022 Nov 23;185(24):4471-4473. doi: 10.1016/j.cell.2022.10.026. 4.Bergmann C, Müller F,et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rhe...
相关研究结果发表在2021年8月5日的NEJM期刊上,论文标题为“CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus”。 系统性红斑狼疮是一种自身免疫性疾病,可导致全身器官损伤。论文通讯作者、埃朗根-纽伦堡大学的Georg Schett博士说,这名女性是世界上第一个用CAR-T细胞治疗的狼疮患者。这意味着在...
CD19 CAR-T细胞疗法推动了血液瘤肿瘤治疗范式的转变,不过由于抗原逃逸和低持久性,仍有一部分患者在治疗后复发,同时,降低成本也是基于病毒载体CAR-T细胞疗法的一个重要挑战。一篇名为“Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system”的文章...
Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and/or additional cytokine support. However, the need for prior conditioning ...
CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy. The high efficacy of CAR T cells in B-...
OBJECTIVE To investigate the efficacy and adverse reaction of CD19-targeted chimeric antigen receptor T cells (CAR-T)in the treatment of relapsed/refractory diffuse large B-cell lymphoma(R/R DLBCL),so as to provide an evidence-based basis for more reasonable and efficient application of CAR-T....
Following engineering, cells were combined with either control T cells or CD19-targeted CAR T cells (CART19). Co-cultures were collected 24 h later and underwent next-generation sequencing to identify which guide RNAs had been enriched in the surviving CART19-exposed cells, reflecting that ...